2023
It is strongly recommended to not conduct, fund, or publish research studies that use spot urine samples with estimating equations to assess individuals’ sodium (salt) intake in association with health outcomes: a policy statement of the World Hypertension League, International Society of Hypertension and Resolve to Save Lives
Campbell N, Whelton P, Orias M, Cobb L, Jones E, Garg R, Willliams B, Khan N, Chia Y, Jafar T, Ide N. It is strongly recommended to not conduct, fund, or publish research studies that use spot urine samples with estimating equations to assess individuals’ sodium (salt) intake in association with health outcomes: a policy statement of the World Hypertension League, International Society of Hypertension and Resolve to Save Lives. Journal Of Hypertension 2023, 41: 683-686. PMID: 36723484, PMCID: PMC10090307, DOI: 10.1097/hjh.0000000000003385.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsSpot urine samplesSodium intakeIndividual sodium intakeWorld Hypertension LeagueHealth outcomesUrine samplesHealth outcome associationsOutcome associationsInternational SocietyDietary sodiumHealth OrganizationIntakeHypertensionHealth impactsShort durationOutcomesAssociationSubstantial controversyLiterature reviewPolicy statements
2022
Three Times Weekly Dosing of Daprodustat versus Conventional Epoetin for Treatment of Anemia in Hemodialysis Patients
Coyne DW, Singh AK, Lopes RD, Bailey CK, DiMino TL, Huang C, Connaire J, Rastogi A, Kim SG, Orias M, Shah S, Patel V, Cobitz AR, Wanner C. Three Times Weekly Dosing of Daprodustat versus Conventional Epoetin for Treatment of Anemia in Hemodialysis Patients. Clinical Journal Of The American Society Of Nephrology 2022, 17: 1325-1336. PMID: 35918106, PMCID: PMC9625096, DOI: 10.2215/cjn.00550122.Peer-Reviewed Original ResearchConceptsErythropoiesis-stimulating agentsTimes weekly dosingTRIAL REGISTRY NAMESecondary end pointsTreatment of anemiaEpoetin groupDaprodustat groupEnd pointWeekly dosingREGISTRY NAMEHemoglobin valuesMean changeHypoxia-inducible factor prolyl hydroxylase inhibitorCLINICAL TRIAL REGISTRY NAMEPrincipal secondary end pointTreatment-emergent adverse eventsIntravenous iron doseIntravenous iron usePrimary end pointChronic kidney diseaseMean hemoglobin valuesEvaluation periodProlyl hydroxylase inhibitorBaseline hemoglobinPrevalent hemodialysisBedtime dosing of antihypertensive medications: systematic review and consensus statement: International Society of Hypertension position paper endorsed by World Hypertension League and European Society of Hypertension
Stergiou G, Brunström M, MacDonald T, Kyriakoulis KG, Bursztyn M, Khan N, Bakris G, Kollias A, Menti A, Muntner P, Orias M, Poulter N, Shimbo D, Williams B, Adeoye AM, Damasceno A, Korostovtseva L, Li Y, Muxfeldt E, Zhang Y, Mancia G, Kreutz R, Tomaszewski M. Bedtime dosing of antihypertensive medications: systematic review and consensus statement: International Society of Hypertension position paper endorsed by World Hypertension League and European Society of Hypertension. Journal Of Hypertension 2022, 40: 1847-1858. PMID: 35983870, DOI: 10.1097/hjh.0000000000003240.Peer-Reviewed Original ResearchConceptsAntihypertensive drugsAntihypertensive medicationsBedtime dosingOutcome trialsDrug dosingClinical practiceEfficient medical interventionsHypertension position paperMorning BP surgeNight-time hypertensionAntihypertensive drug therapyAntihypertensive drug treatmentSingle morning doseBlood pressure profileEffective treatment strategiesWorld Hypertension LeagueInternational SocietyAntihypertensive treatmentBedtime administrationBP controlBP surgeMorning doseMorning dosingCardiovascular eventsAdverse prognosis2022 World Hypertension League, Resolve To Save Lives and International Society of Hypertension dietary sodium (salt) global call to action
Campbell NRC, Whelton PK, Orias M, Wainford RD, Cappuccio FP, Ide N, Neal B, Cohn J, Cobb LK, Webster J, Trieu K, He FJ, McLean RM, Blanco-Metzler A, Woodward M, Khan N, Kokubo Y, Nederveen L, Arcand J, MacGregor GA, Owolabi MO, Lisheng L, Parati G, Lackland DT, Charchar FJ, Williams B, Tomaszewski M, Romero CA, Champagne B, L’Abbe M, Weber MA, Schlaich MP, Fogo A, Feigin VL, Akinyemi R, Inserra F, Menon B, Simas M, Neves MF, Hristova K, Pullen C, Pandeya S, Ge J, Jalil JE, Wang JG, Wideimsky J, Kreutz R, Wenzel U, Stowasser M, Arango M, Protogerou A, Gkaliagkousi E, Fuchs FD, Patil M, Chan AW, Nemcsik J, Tsuyuki RT, Narasingan SN, Sarrafzadegan N, Ramos ME, Yeo N, Rakugi H, Ramirez AJ, Álvarez G, Berbari A, Kim CI, Ihm SH, Chia YC, Unurjargal T, Park HK, Wahab K, McGuire H, Dashdorj NJ, Ishaq M, Ona DID, Mercado-Asis LB, Prejbisz A, Leenaerts M, Simão C, Pinto F, Almustafa BA, Spaak J, Farsky S, Lovic D, Zhang XH. 2022 World Hypertension League, Resolve To Save Lives and International Society of Hypertension dietary sodium (salt) global call to action. Journal Of Human Hypertension 2022, 37: 428-437. PMID: 35581323, PMCID: PMC9110933, DOI: 10.1038/s41371-022-00690-0.Peer-Reviewed Original ResearchImplementación de la Iniciativa HEARTS en Argentina: primeros resultados
Rodriguez G, Rosende A, Prado C, Mariño R, Irazola V, DiPette D, Orias M, Arcila G, Laspiur S. Implementación de la Iniciativa HEARTS en Argentina: primeros resultados. BULL PAN AM HEALTH ORGAN 2022, 46: e181. PMID: 36160765, PMCID: PMC9491484, DOI: 10.26633/rpsp.2022.181.Peer-Reviewed Original ResearchCombination therapyHearts InitiativePrimary health care centersStandardized treatment protocolMain risk factorsHealth care centersCause of mortalityBlood pressure measurement devicesArterial hypertensionRisk factorsCare centerTherapy levelsCardiovascular diseaseHealth centersTreatment protocolHealth teamsBaseline valuesParadoxical decreasePressure measurement deviceClinical competencyPeriod of restrictionHypertensionGeneralized reductionCOVID-19Therapy
2021
Is Isolated Diastolic Hypertension an Important Phenotype?
Romero CA, Tabares AH, Orias M. Is Isolated Diastolic Hypertension an Important Phenotype? Current Cardiology Reports 2021, 23: 177. PMID: 34657205, PMCID: PMC8753786, DOI: 10.1007/s11886-021-01609-w.Peer-Reviewed Original ResearchConceptsNarrow pulse pressureDiastolic hypertensionCardiovascular riskPulse pressureLong-term cardiovascular riskRecent FindingsRecent guidelinesHypertension subgroupIDH definitionsIDH prevalenceHypertensive patientsYounger patientsRisk stratificationEpidemiological characteristicsTherapeutic decisionsPharmacological interventionsHypertension phenotypesCutoff levelHypertensionImportant subgroupPatientsPathophysiologyRiskSubgroupsIDHLong termASCEND-TD: A Randomized, Double-Blind, Active-Controlled Study of Daprodustat Administered Three Times Weekly in Hemodialysis Patients
Coyne D, Singh A, Lopes R, Bailey C, Dimino T, Huang C, Connaire J, Rastogi A, Kim S, Orias M, Shah S, Patel V, Cobitz A, Wanner C. ASCEND-TD: A Randomized, Double-Blind, Active-Controlled Study of Daprodustat Administered Three Times Weekly in Hemodialysis Patients. Journal Of The American Society Of Nephrology 2021, 32: 191-191. DOI: 10.1681/asn.20213210s1191b.Peer-Reviewed Original ResearchErratum to “Second Consensus on Treatment of Patients Recently Diagnosed with Mild Hypertension and Low Cardiovascular Risk”. [YMCD 45/10 (October 2020) 100653]
Morales-Salinas A, Olsen M, Kones R, Kario K, Wang J, Beilin L, Weber M, Yano Y, Burrell L, Orias M, Dzudie A, Lavie C, Ventura H, Sundström J, de Simone G, Coca A, Rumana U, Marrugat J. Erratum to “Second Consensus on Treatment of Patients Recently Diagnosed with Mild Hypertension and Low Cardiovascular Risk”. [YMCD 45/10 (October 2020) 100653]. Current Problems In Cardiology 2021, 46: 100877. PMID: 34148707, DOI: 10.1016/j.cpcardiol.2021.100877.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsLlamado a la acción de San Pablo para la prevención y el control de la hipertensión arterial, 2020
Campbell NR, Schutte AE, Varghese CV, Ordunez P, Zhang XH, Khan T, Sharman JE, Whelton PK, Parati G, Weber MA, Orías M, Jaffe MG, Moran AE, Plavnik FL, Ram VS, Brainin M, Owolabi MO, Ramirez AJ, Barbosa E, Bortolotto LA, Lackland DT. Llamado a la acción de San Pablo para la prevención y el control de la hipertensión arterial, 2020. BULL PAN AM HEALTH ORGAN 2021, 45: 1. PMID: 33643404, PMCID: PMC7905751, DOI: 10.26633/rpsp.2021.26.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements
2020
Standardized treatment to improve hypertension control in primary health care: The HEARTS in the Americas Initiative
DiPette DJ, Goughnour K, Zuniga E, Skeete J, Ridley E, Angell S, Brettler J, Campbell NRC, Coca A, Connell K, Doon R, Jaffe M, Lopez‐Jaramillo P, Moran A, Orias M, Pineiro DJ, Rosende A, González YV, Ordunez P. Standardized treatment to improve hypertension control in primary health care: The HEARTS in the Americas Initiative. Journal Of Clinical Hypertension 2020, 22: 2285-2295. PMID: 33045133, PMCID: PMC8029673, DOI: 10.1111/jch.14072.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsAntihypertensive medicationsCardiovascular diseaseTreatment protocolHypertension controlBurden of CVDCVD secondary preventionEffective antihypertensive medicationsMajor hypertension guidelinesRisk factor mitigationControl of hypertensionFixed-dose combinationPrimary health carePost-program implementationCommunity-based programsHypertension guidelinesSecondary preventionBlood pressureCVD burdenInitial treatmentPharmacologic protocolRisk factorsStandardized treatmentMedication formulariesSingle pillHypertensionGlobal Dialysis Perspective: Argentina.
Orias M, Rosa Diez GJ. Global Dialysis Perspective: Argentina. Kidney360 2020, 1: 676-679. PMID: 35372938, PMCID: PMC8815540, DOI: 10.34067/kid.0001222019.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsSecond Consensus on Treatment of Patients Recently Diagnosed With Mild Hypertension and Low Cardiovascular Risk
Morales-Salinas A, Olsen MH, Kones R, Kario K, Wang J, Beilin L, Weber MA, Yano Y, Burrell L, Orias M, Cameroon DA, Lavie CJ, Ventura H, Sundström J, de Simone G, Coca A, Rumana U, Marrugat J. Second Consensus on Treatment of Patients Recently Diagnosed With Mild Hypertension and Low Cardiovascular Risk. Current Problems In Cardiology 2020, 45: 100653. PMID: 32828558, DOI: 10.1016/j.cpcardiol.2020.100653.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsHypertension and kidney disease progression.
Rigo D, Orias M. Hypertension and kidney disease progression. Clinical Nephrology 2020, 93: 103-107. PMID: 31549630, DOI: 10.5414/cnp92s118.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsChronic kidney diseaseKidney disease progressionDisease progressionCases of CKDHypertension-attributed nephropathyRisk of progressionAfrican American patientsGene risk variantsClinical suspicionHypertensive nephropathyKidney diseaseUnknown etiologyCommon findingProgressionHypertensionNephropathyPatientsRisk variantsGenetic backgroundEtiologyDiseaseDiagnosisSuspicion
2016
2016 Dietary Salt Fact Sheet and Call to Action: The World Hypertension League, International Society of Hypertension, and the International Council of Cardiovascular Prevention and Rehabilitation
Campbell NR, Lackland DT, Niebylski ML, Orias M, Redburn KA, Nilsson PM, Zhang X, Burrell L, Horiuchi M, Poulter NR, Prabhakaran D, Ramirez AJ, Schiffrin EL, Schutte AE, Touyz RM, Wang J, Weber MA, Prevention and Rehabilitation I. 2016 Dietary Salt Fact Sheet and Call to Action: The World Hypertension League, International Society of Hypertension, and the International Council of Cardiovascular Prevention and Rehabilitation. Journal Of Clinical Hypertension 2016, 18: 1082-1085. PMID: 27515460, PMCID: PMC8032122, DOI: 10.1111/jch.12894.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsHigh Blood Pressure 2016: Why Prevention and Control Are Urgent and Important. The World Hypertension League, International Society of Hypertension, World Stroke Organization, International Diabetes Foundation, International Council of Cardiovascular Prevention and Rehabilitation, International Society of Nephrology
Campbell NR, Khalsa T, Executive: W, Lackland DT, Niebylski ML, Nilsson PM, Redburn KA, Orias M, Zhang X, Executive: I, Burrell L, Horiuchi M, Poulter NR, Prabhakaran D, Ramirez AJ, Schiffrin EL, Touyz RM, Wang J, Weber MA, Organization W, Federation I, Prevention and Rehabilitation I, Society of Nephrology I. High Blood Pressure 2016: Why Prevention and Control Are Urgent and Important. The World Hypertension League, International Society of Hypertension, World Stroke Organization, International Diabetes Foundation, International Council of Cardiovascular Prevention and Rehabilitation, International Society of Nephrology. Journal Of Clinical Hypertension 2016, 18: 714-717. PMID: 27316336, PMCID: PMC8031792, DOI: 10.1111/jch.12840.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements
2015
Clinical practice of ambulatory versus home blood pressure monitoring in hypertensive patients.
Paolasso JA, Crespo F, Arias V, Moreyra EA, Volmaro A, Orías M, Moreyra E. Clinical practice of ambulatory versus home blood pressure monitoring in hypertensive patients. Blood Pressure Monitoring 2015, 20: 303-9. PMID: 26110369, DOI: 10.1097/MBP.0000000000000138.Peer-Reviewed Original ResearchResources for Blood Pressure Screening Programs in Low Resource Settings: A Guide From the World Hypertension League
Mangat BK, Campbell N, Mohan S, Niebylski ML, Khalsa TK, Berbari AE, Cloutier L, Jean-Charles R, Kenerson J, Lemogoum D, Orias M, Veiga E, Zhang XH. Resources for Blood Pressure Screening Programs in Low Resource Settings: A Guide From the World Hypertension League. Journal Of Clinical Hypertension 2015, 17: 418-420. PMID: 25689038, PMCID: PMC8031891, DOI: 10.1111/jch.12499.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsNovel RAAS agonists and antagonists: clinical applications and controversies
Romero CA, Orias M, Weir MR. Novel RAAS agonists and antagonists: clinical applications and controversies. Nature Reviews Endocrinology 2015, 11: 242-252. PMID: 25666495, PMCID: PMC7097622, DOI: 10.1038/nrendo.2015.6.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsAngiotensin receptor blockersRelative risk reductionBlood pressure homeostasisRAAS peptidesAldosterone systemReceptor blockersCardiorenal diseaseVascular injuryPressure homeostasisReceptor densityTarget organsAutocrine systemEnzyme inhibitorsVascular structuresClinical applicationRisk reductionVariety of sitesHaemodynamicsBlockersAgonistsInjuryAntagonistRAASDiseasePeptidesLos trastornos Nefrourológicos. Insuficiencia Renal Crónica
Barron Belen, Orias M, 2015. Los trastornos Nefrourológicos. Insuficiencia Renal Crónica. In Greca, Gallo, Parodi, Carlson (Eds.) Medicina Ambulatoria. pp. 773-780, Corpus, Second Edition.Books
2014
Novel Molecules
Vukelic V, Orias M. Novel Molecules. Clinical Hypertension And Vascular Diseases 2014, 47-55. DOI: 10.1007/978-1-4939-1982-6_5.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsAngiotensin II type 2 receptor agonistType 2 receptor agonistBlood pressure controlEnd-organ damageEndothelin receptor antagonistsAldosterone synthase inhibitorsNew therapeutic approachesSoluble epoxide hydrolase inhibitorsSoluble guanylyl cyclaseEpoxide hydrolase inhibitorAldosterone axisHypertension treatmentVasopeptidase inhibitorReceptor antagonistReceptor agonistRecombinant renalaseTherapeutic approachesNew agentsSynthase inhibitorAnimal modelsRenin inhibitorsPressure controlGuanylyl cyclaseAdverse effectsHydrolase inhibitors